Want to see ABCL full AI Analyst Report?
ABCL Stock Chart & Stats
$12.50
-$0.03(-0.56%)
At close: 4:00 PM EDT
$12.50
-$0.03(-0.56%)
Day’s Range― - ―
52-Week Range$2.75 - $13.18
Previous CloseN/A
Volume984.13K
Average Volume (3M)6.62M
Market Cap
$4.10B
Enterprise Value$1.97K
Total Cash (Recent Filing)$540.10M
Total Debt (Recent Filing)$135.62M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
Nov 10, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.54
Shares Outstanding324,047,360
10 Day Avg. Volume4,490,676
30 Day Avg. Volume6,624,698
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)1.06
Price to Sales (P/S)13.60
P/FCF Ratio-5.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.57Price Target Upside32.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.67
Revenue Forecast (FY)$25.17M
Bulls Say, Bears Say
Bulls Say
Strong Liquidity RunwayThe substantial liquidity base gives AbCellera capacity to fund internal clinical programs and platform investment without immediate financing pressure. Management indicates resources support at least three years of pipeline investment, improving strategic flexibility while programs mature.
Strategic Partnership TractionVertex adds external validation for AbCellera’s T-cell engager platform while transferring research and development funding responsibility to a major partner. Upfront payments, milestones, and royalties can diversify future economics and expand AbCellera’s role across biologics development.
Low Financial LeverageLow leverage and a sizable equity base provide financial resilience as AbCellera funds loss-making research and clinical programs. Limited debt reduces fixed financing obligations and preserves more flexibility to allocate capital toward pipeline development and partnerships.
Bears Say
Declining Revenue And Deep LossesRevenue contraction alongside very large operating and net losses shows that the current cost base is not supported by recurring business activity. Sustained losses could require continued funding and make earnings dependent on successful program progression or new partner economics.
Persistent Negative Cash GenerationNegative operating and free cash flow indicate that AbCellera is consuming cash rather than self-funding its pipeline. The shift from positive cash generation in earlier periods increases dependence on liquidity, financing, collaboration payments, and successful execution to sustain investment.
Clinical And Collaboration DependenceThe company’s near-term value creation depends on clinical outcomes and partner-funded programs rather than established product revenue. ABCL635 efficacy remains uncertain because placebo response and target biology may affect results, while collaboration-based income can vary with program milestones.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $2.75 and its highest was $13.18 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $4.10B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Nov 10, 2026 which is in 47 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Aug 05, 2026. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.164 by -$0.016.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.17.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 324,047,360 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.164. Following the earnings report the stock price went up 10.304%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.57 (32.57% Upside)
$16.57 (32.57% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 81%
Sector Average 63%
Sector Average 63%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 1.9%
Last 30 Days ▲ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
151.22%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.74%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
AbCellera Biologics
AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveys a cautiously optimistic outlook: the company is well capitalized with substantial upfront partnership cash, large potential deal value, and multiple near-term clinical catalysts (notably ABCL635 topline readout and ABCL575 Phase I readout). Those positives are tempered by a sharp year-over-year revenue decline (~-76.5%), a wider net loss (+57.1%), increased R&D spend, and remaining scientific and placebo-related risks for the lead program. On balance, the strong liquidity position and strategic partnerships alongside clear near-term catalysts outweigh the financial pressures and programmatic risks in the short term.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$16.57
▲(32.57% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
38.60% Insiders
4.40% Mutual Funds
18.51% Other Institutional Investors
37.18% Public Companies and Individual Investors